Synovial Sarcoma Market to Exhibit a CAGR of 16.14% During the Forecast Period of 2018-2030, States DelveInsight
FDA Breakthrough Therapy Designation in MAGE-A4 expressing patients. The Synovial Sarcoma market is expected to show positive growth, mainly ascribed to the increased prevalence and the anticipated launch of novel therapies, such as Anlotinib, ADP-A2M4, For further information on Market Impact by Therapies, visit: Synovial Sarcoma, also known as malignant synovioma, can originate from different soft tissue types, such as muscle or ligaments. It is a high-grade tumor and spreads to distant sites. Synovial Sarcoma symptoms depend on where the tumor forms. The disease is often first noticed a...
Source: prnewswire.com